Bionime Corp (4737) - Total Assets
Based on the latest financial reports, Bionime Corp (4737) holds total assets worth NT$5.58 Billion TWD (≈ $175.95 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4737 book value for net asset value and shareholders' equity analysis.
Bionime Corp - Total Assets Trend (2009–2024)
This chart illustrates how Bionime Corp's total assets have evolved over time, based on quarterly financial data.
Bionime Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Bionime Corp's total assets of NT$5.58 Billion consist of 30.7% current assets and 69.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 5.6% |
| Accounts Receivable | NT$722.82 Million | 12.5% |
| Inventory | NT$571.14 Million | 9.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$776.08 Million | 13.4% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Bionime Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bionime Corp market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bionime Corp's current assets represent 30.7% of total assets in 2024, a decrease from 80.9% in 2009.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2024, down from 39.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 13.4% of total assets.
Bionime Corp Competitors by Total Assets
Key competitors of Bionime Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alcon AG
SW:ALC
|
Switzerland | CHF31.53 Billion |
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
USA | $32.49 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
Bionime Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.75 | 0.84 | 1.17 |
| Quick Ratio | 0.51 | 0.56 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-471.19 Million | NT$-319.73 Million | NT$216.26 Million |
Bionime Corp - Advanced Valuation Insights
This section examines the relationship between Bionime Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.34 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 9.1% |
| Total Assets | NT$5.78 Billion |
| Market Capitalization | $151.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bionime Corp's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bionime Corp's assets grew by 9.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bionime Corp (2009–2024)
The table below shows the annual total assets of Bionime Corp from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.78 Billion ≈ $182.14 Million |
+9.07% |
| 2023-12-31 | NT$5.30 Billion ≈ $167.00 Million |
+6.37% |
| 2022-12-31 | NT$4.98 Billion ≈ $156.99 Million |
+9.18% |
| 2021-12-31 | NT$4.56 Billion ≈ $143.79 Million |
+1.76% |
| 2020-12-31 | NT$4.49 Billion ≈ $141.30 Million |
+1.83% |
| 2019-12-31 | NT$4.40 Billion ≈ $138.76 Million |
-4.03% |
| 2018-12-31 | NT$4.59 Billion ≈ $144.59 Million |
+4.90% |
| 2017-12-31 | NT$4.37 Billion ≈ $137.83 Million |
-5.85% |
| 2016-12-31 | NT$4.65 Billion ≈ $146.39 Million |
+1.74% |
| 2015-12-31 | NT$4.57 Billion ≈ $143.89 Million |
-2.14% |
| 2014-12-31 | NT$4.67 Billion ≈ $147.04 Million |
+3.16% |
| 2013-12-31 | NT$4.52 Billion ≈ $142.54 Million |
+24.56% |
| 2012-12-31 | NT$3.63 Billion ≈ $114.43 Million |
+27.40% |
| 2011-12-31 | NT$2.85 Billion ≈ $89.82 Million |
+121.51% |
| 2010-12-31 | NT$1.29 Billion ≈ $40.55 Million |
+44.28% |
| 2009-12-31 | NT$892.09 Million ≈ $28.11 Million |
-- |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offers blood glucose monitoring devices and systems under the RIGHTEST… Read more